After years of debate the REACH legislation comes into force in June 2007. It will replace over 40 national chemical legislations with one harmonized policy. REACH is short for Registration, Evaluation and Authorisation of Chemicals. The policy requires industry to register all existing and new substances with a new European Chemicals Agency, based in Helsinki, Finland.
CASCADE Network of Excellence invites all interested parties to an open session about the new REACH legislation. The session will serve as a platform for open discussions on the implications of the policy from different stakeholder perspectives. Short presentations will be followed by a moderated panel debate. The question we will try to answer is: How will consumers, industry, NGOs, authorities and researchers accommodate their activities to the new reality under REACH?
When: April 18, 2007, from 13.30 to 16.30
Where: Biomedicum, Haartmaninkatu 8, Helsinki, Finland
Agenda:
Welcome – Introduction by moderator Henrik Ekman, science journalist.
Heikki Salonen, Finnish Environment Institute (SYKE)
What is REACH and the new European Chemicals Agency in Helsinki?
Jari Luukkonen, WWF
Environmental NGOs and the REACH.
Göran Wall, Swedish Plastics and Chemicals Federation
How will the chemical industry implement REACH?
Bengt Fjällborg, Akzo Nobel
REACH activities at Akzo Nobel Surfactants – a change of direction?
Annikka Marniemi, Finnish Consumer Association
The consumer perspective on REACH.
Joan-Albert Vericat, Neuropharma & In Vitro Testing Industrial Platform (IVTIP)
In vitro methods for testing of chemicals. Presentation of the view of IVTIP.
Jan-Åke Gustafsson, coordinator CASCADE Network of Excellence
CASCADE integrated test system for chemicals.
Panel discussion, including questions from the auditorium.
Media is invited to the session. Time for face-to-fact interviews with CASCADE coordinator Jan-Åke Gustafsson and other speakers can be arranged.
For more information, please contact:
Cecilia Johansson, Communication Manager CASCADE, Karolinska Institutet,
Tel: +46 8 608 92 37, +46 702 544 657 (mobile)
Email: c.johansson.cascade@biosci.ki.se
28 February, 2023 - Karolinska Institutet
Following a successful pilot study, an online anonymous treatment program aimed at reducing child sexual abuse by providing treatment to individuals who exhibit sexual urges towards children is being launched across the EU. It is now available in Swedish, German, and Portuguese as well as in an updated English version. The treatment program, which has […]
29 April, 2021 - Karolinska Institutet
Researchers at Karolinska Institutet and the Public Health Agency of Sweden have studied newborn babies whose mothers tested positive for SARS-CoV-2 during pregnancy or childbirth. The results show that although babies born of test-positive mothers are more likely to be born early, extremely few were infected with COVID-19. The study, which is published in the […]
27 April, 2020 - Karolinska Institutet
Only about five per cent of the babies born to mothers with hepatitis C are themselves infected by the disease. A possible reason for this low figure is that the baby’s immune system has already destroyed the virus before birth. A new study from researchers at KI and published in the journal Gut reveals clear […]
7 April, 2020 - Karolinska Institutet
People with celiac disease have increased risk of dying prematurely, despite increased awareness of the disease in recent years and better access to gluten-free food. This is according to a new study from Karolinska Institutet in Sweden and Columbia University in the U.S. published in the prestigious journal JAMA. Celiac disease was linked to increased […]
Expertsvar, The Swedish Research Council, Hantverkargatan 11B, Stockholm SWEDENPhone +46(0)8 546 44 000
P.O. Box 1035, SE-101 38 Stockholm, expertsvar@vr.se
Information about cookies will open in a new window
